Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Candel Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $11.63M | -43.3% |
| FY2023 | Dec 31, 2023 | $20.53M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $4.23M | -70.0% |
| Q2 FY2025 | Jun 30, 2025 | $6.70M | -59.4% |
| Q1 FY2025 | Mar 31, 2025 | $9.17M | -51.6% |
| Q4 FY2024 | Dec 31, 2024 | $11.63M | -43.3% |
| Q3 FY2024 | Sep 30, 2024 | $14.08M | -31.1% |
| Q2 FY2024 | Jun 30, 2024 | $16.51M | -18.9% |
| Q1 FY2024 | Mar 31, 2024 | $18.94M | -6.6% |
| Q4 FY2023 | Dec 31, 2023 | $20.53M | – |
| Q3 FY2023 | Sep 30, 2023 | $20.44M | – |
| Q2 FY2023 | Jun 30, 2023 | $20.36M | – |
| Q1 FY2023 | Mar 31, 2023 | $20.28M | – |
See a number that looks wrong?